SynthesisEuropean respiratory review : an official journal of the European Respiratory Society2019
Does cytoreduction surgery and hyperthermic intrathoracic chemotherapy prolong survival in patients with N0-N1 nonsmall cell lung cancer and malignant pleural effusion?
Synthesis in European respiratory review : an official journal of the European Respiratory Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Trial
- ERS Congress 2025: highlights from the Thoracic Surgery and Lung Transplantation Assembly.ERJ open research · 2026Article
- The utility of a pleural carcinomatosis score for assessing resectability.Pleura and peritoneum · 2026Article
- Present and future of cytoreductive surgery and hyperthermic intrathoracic chemotherapy for pleural metastases: a narrative review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Dose-Dependent Concentration and Penetration Depth of Cisplatin in Human Lung Tissue During Hyperthermic Exposure.Journal of clinical medicine · 2025Article
- Hyperthermic intrathoracic chemotherapy in overcoming tyrosine kinase inhibitor resistance in a patient with malignant pleural effusion: a case report.Translational lung cancer research · 2025Article
- Medical thoracoscopic photodynamic therapy for metastatic pleural tumors with malignant effusion: an exploratory pilot study.Frontiers in oncology · 2025Article
- Review
- Editorial: Recent advances in surgical management of NSCLC.Frontiers in oncology · 2024Article
- Hyperthermic intrapleural chemotherapy: an update.Journal of thoracic disease · 2023Review
- Outcome after cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy in patients with secondary pleural metastases.Frontiers in oncology · 2023Article
- Long-Term Treatment-Free Survival After Multimodal Therapy in a Patient with Stage IV Lung Adenocarcinoma.OncoTargets and therapy · 2022Article
- A narrative review of hyperthermic intrathoracic chemotherapy for advanced lung cancer.Annals of translational medicine · 2021Review
- Hypertermic Intrathoracic Chemotherapy (HITHOC) for thymoma: a narrative review on indications and results.Annals of translational medicine · 2021Review
- Perioperative anaesthetic management of patients undergoing thoracic cytoreductive surgery and HITHOC.Annals of translational medicine · 2021Review
- Hyperthermic intrathoracic chemotherapy (HITHOC): narrative review of the current literature, recommendations and future studies.Annals of translational medicine · 2021Review
- Narrative review of theoretical considerations regarding HITHOC between past and future.Annals of translational medicine · 2021Review
- Present and future of hyperthermic intrathoracic chemotherapy (HITHOC) in thoracic surgical oncology.Annals of translational medicine · 2021Article
- New horizons in non-small-cell lung cancer patients with ipsilateral pleural dissemination (M1a): review of the literature.Annals of translational medicine · 2021Review
- Medical Thoracoscopic Thermal Ablation Therapy for Metastatic Pleural Tumors with Malignant Effusion: An Exploratory Retrospective Study.International journal of general medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDebulking surgery and hyperthermic intrathoracic chemotherapy (HITHOC) has been successfully used in the treatment of thoracic tumours. Few authors report on the feasibility of its use in patients with lung cancer and malignant pleural effusion. The aim of this study was to evaluate the efficacy and results of debulking surgery and HITHOC in the treatment of selected patients with nonsmall cell lung cancer (NSCLC) and malignant pleural effusion.
methodsA systematic review was conducted in MEDLINE in accordance with PRISMA guidelines. The word search included: "hyperthermic intrathoracic chemotherapy and/or HITHOC or hyperthermic intrapleural". Inclusion criteria were only those studies reporting a sufficient amount of data on HITHOC and surgery for lung cancer. Single case reports and review articles were excluded.
results20 articles were selected as they related to the topic of HITHOC and lung cancer. Most were from China (n=8) and Japan (n=6). Only four out of the 20 articles had sufficient data for this review. In total, data for 21 patients were collected. Debulking surgery ranged from wedge resection to pneumonectomy and pleurectomy. Mean survival was 27 months and median survival was 18 months (range 1-74 months). 13 patients out of 21 (62%) were alive at 1 year and six (28.5%) were alive at 2 years. 10 patients were still alive at the time of the respective publication in the 21 patients included. Systemic toxicity and treatment-related mortality were nil. There were insufficient data to perform a meta-analysis.
conclusionAlthough reported survival in this systematic review is encouraging, available evidence concerning debulking surgery and HITHOC in N0-N1 NSCLC with malignant pleural effusion is weak. Better evidence in the form of a randomised controlled trial is mandatory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.